Deep Learning on Amyloid Positons Emission Tomography
Recruiting · NCT07309107 · Observational (researchers observe without assigning treatment) · Lead sponsor: Central Hospital, Nancy, France
View the official record on ClinicalTrials.gov →What this trial is about
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.
Who can take part
Age range
18 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with objective cognitive impairment,
- Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,
Exclusion criteria
- Patient have objected to the use of their data.
Where it is running
3 locations listed.
- CHRU NANCY Brabois, nuclear medicine department - Vandœuvre-lès-Nancy, France
- Nancy's hospital - Vandœuvre-lès-Nancy, France
- Nuclear medicine department CHRU de NANCY Brabois - Vandœuvre-lès-Nancy, France